HEM News Briefs

Switching to BAY 81-8973 Could Help Optimize Hemophilia Treatment

Patients with hemophilia A who switched to BAY 81-8973 (octocog alfa; Kovaltry®) from other standard half-life (SHL) factor VIII (FVIII) products maintained already favorable outcome rates with a possible improvement in half-life, as published in Haemophilia. The patients enrolled in the study had a median annualized bleeding rate (ABR) and annualized joint bleeding rate (AJBR)…

Patients With Hemophilia Often Given Potentially Inappropriate Medications

The exposure to potentially inappropriate medications is higher among older patients with hemophilia and von Willebrand disease than the general population of older individuals, according to the results of a multicentre prospective observational study called M’HEMORRH-AGE. “Interventions focusing on deprescription of these inappropriate medications should be conducted in this specific population,” the authors said in…

Hemarthrosis

Despite Treatment, Hemarthroses Common in Patients With Severe Hemophilia

A new study out of the UK found that only one-third of adults and two-thirds of children with severe hemophilia A and B (HA/HB) were free of hemarthroses in 2018, despite all patients reporting high treatment compliance. The study, published in BMJ Open, utilized data from a patient-reported online diary, Haemtrack, and the Hemophilia Joint…

Study Shows Risk-Benefit of Emicizumab Unchanged in Hemophilia A

Increased risk of thrombotic events (TEs), especially thrombotic microangiopathies (TMAs), occurred with concomitant use of emicizumab, according to an updated safety analysis presented at the 63rd American Society for Hematology Annual Meeting & Exposition. Prothrombin complex concentrate (aPCC) was activated to prophylactically treat individuals with congenital hemophilia A with and without factor VIII inhibitors. No…

New Genotyping Strategy Could Identify Color Blindness in Hemophilia

Researchers in Taiwan developed a new genotyping strategy that can reliably identify color blindness among patients with hemophilia A, as published in Talanta. Their method could be useful in many fields including disease diagnosis, polymorphisms analysis, and quantitative assays. The development of the new method stems from the fact that traditional genetic analysis methods are…

Novel Technology Induces FVIII Production in Hemophilia A Rodent Model

Ultrasound-mediated gene delivery (UMGD) successfully transferred factor VIII (FVIII) plasmids through a hepatocyte-specific promoter into the livers of mice with hemophilia and achieved persistent and therapeutic levels of FVIII expression, according to a new study published in Molecular Therapy: Nucleic Acid. Hemophilia A is an X-linked disease caused by a deficiency in FVIII. Conventional therapy…

Behavioral Change Techniques Support Patients With Hemophilia

Patients with hemophilia who were given a free gym membership and personal training had increased activity, according to a new study published in Research and Practice in Thrombosis and Haemostasis. The study showed that adding the personal trainer to the free gym membership motivated the patients to conduct training and maintain physical activity. “This is…

Real-World Data Show Shortcomings of Prophylactic FVIII for Hemophilia

Researchers discovered shortcomings associated with factor VIII (FVIII) prophylaxis treatment for patients with severe hemophilia A, as published in the Journal of Clinical Medicine. Prophylactic exogenous FVIII is recommended for individuals with severe hemophilia A. However, reports of bleeding events suggest that it is not a cure. “Although recent advances in hemophilia treatment and management…

Emicizumab and Fc Fusion Protein Remain Effective for Hemophilia A

Researchers reported that both emicizumab and Fc fusion protein (rFVIIIFc) recorded lower bleeding rates compared to prior factor VIII (FVIII) therapies for patients with hemophilia A, as presented at the 63rd American Society for Hematology Annual Meeting & Exposition. Hemophilia A is a bleeding disorder characterized by FVIII deficiency. Patients with hemophilia A suffer from…

Efanesoctocog Alfa Shows VWF-Independent Results in Hemophilia A

The half-life of efanesoctocog alfa does not appear to be related to endogenous von Willebrand factor (VWF) antigen levels in the treatment of hemophilia A, according to a new post hoc analysis presented at the 63rd American Society for Hematology Annual Meeting & Exposition. Efanesoctocog alfa is an investigational recombinant factor VIII (rFVIII) treatment. The…

Next post in HEM News Briefs